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Abstract
Background: Whether mitral leaflet elongation is a primary phenotype of hypertrophic cardiomyopathy (HCM) is
controversial. We investigated the genetic relevance and determinants of mitral leaflet size by performing extensive
gene analyses in patients with HCM.
Methods: Anterior mitral leaflet (AML) lengths were measured in HCM patients (n = 211) and age- and sex-matched
controls (n = 30) using echocardiography with hemodynamic and chamber geometric assessments. We analyzed 82
nuclear DNA (8 sarcomeric genes, 74 other HCM-associated genes) and mitochondrial DNA. Cardiac magnetic
resonance imaging (CMR) was performed in the 132 HCM patients.
Results: Average indexed AML was significantly longer for HCM than for controls (17.2 ± 2.3 vs. 13.3 ± 1.6 mm/m2,
P < 0.001). Average AML length correlated with body surface area (BSA), left ventricular (LV) end-systolic volume
(P < 0.001) and LV mass by CMR (P < 0.001). Average indexed AML by BSA of pure-apical HCM was significantly
shorter than other typed HCM (16.6 ± 2.0 vs. 17.4 ± 2.4 mm/m2, P = 0.025). Indexed AML was independently
correlated with left atrial wall stress. The thin filament mutation group showed larger average AML (31.9 ± 3.8 vs.
29.6 ± 3.8 mm, P = 0.045), but this was not significant with the indexed value. No difference in AML size among
subgroups was observed based on the presence of sarcomere protein or mitochondria-related gene variants (P >
0.05).
Conclusion: AML elongation was a unique finding of HCM. However, the leaflet size was more related to chamber
geometry and hypertrophy pattern rather than genetic factors within overt HCM.
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Introduction
Mitral leaflet elongation is related to obstructive hyper-
trophic cardiomyopathy (HCM) [1]. Although, there are
still some controversies whether classical pathogenic
sarcomere gene variants independently affect mitral leaf-
let enlargement [2–4]. Previous basic studies have shown
that some sarcomere genes affect valvular growth [5, 6].
In addition, a recent study further confirmed that leaflet
elongation is a primary phenotype in subclinical HCM
patients with pathogenic sarcomere gene mutations [7].
However, these investigations mainly focused on variants
in classical pathogenic sarcomere genes such as
MYBPC3 and MYH7, regardless of the morphologic
phenotype of the hypertrophy pattern [2–4, 7]. The con-
tributions of various gene variant groups other than
sarcomere genes have not been extensively investigated.
In addition, about 40–60% of patients with overt HCM
do not have any pathogenic sarcomere gene mutations
[4]. Furthermore, regarding mitral leaflet size, there was
no comparison study between pathogenic variant group
and non-variant group within overt hypertrophy pa-
tients. Therefore, it is still unclear whether mitral leaflet
size in overt HCM is mainly determined by genotype or
by additional geometric or hemodynamic factors. In this
study, to reveal the genetic relevance and effects of LV
geometric change to mitral leaflet size, an extensive
HCM gene panel comprising 82 nuclear DNA (nDNA)
genes (8 sarcomere genes, 74 other HCM-associated
genes) and mitochondrial DNA (mtDNA) genes was an-
alyzed along with diverse morphologic phenotype defini-
tions and hemodynamic factors.
Methods
Study population
A total of 432 patients treated at a single center were en-
rolled in an HCM Registry from 2006 to 2014. Among
them, 220 patients were excluded due to insufficient
data, follow-up loss, or declining study enrollment. Of
these patients, one had poor image quality that pre-
cluded measuring mitral leaflet size in any view. Finally,
211 patients underwent genetic testing. The patients en-
rolled in the study had maximal left ventricular (LV)
hypertrophy greater than 13mm and a ratio of maximal
thickness to posterior wall thickness greater than 1.3
without an underlying cause of hypertrophy, such as un-
controlled hypertension or aortic stenosis. Cases of ab-
normal papillary muscle insertion to the apex with
thickening were also included. Patterns of LV hyper-
trophy were classified as apical HCM (ApHCM) and
non-ApHCM (asymmetrical hypertrophy, diffuse hyper-
trophy, and focal segmental hypertrophy). ApHCM was
classified as pure apical type (hypertrophy confined
below the papillary muscle level) and mixed type (mixed
pure apical and asymmetrical septal hypertrophy but
maximal thickness in the apex) according to echocardio-
graphic findings. All patients underwent screening ana-
lysis for Fabry disease and were confirmed negative for
the galactosidase alpha (GLA) variant. For comparison,
anterior mitral leaflet (AML) size was measured in 30
age- and sex-matched controls. The study protocol was
approved by our institutional review board (3–2015-
0019), and written informed consent was obtained for
each subject.
Genetic testing and analysis
HCM gene panel (nDNA) design
A literature search of the PubMed database was per-
formed for targeted gene selection for the comprehen-
sive HCM-specific panel. It included 82 nDNA genes
(33 sarcomere protein genes, 5 phenocopy genes, and 44
nuclear genes linked to mitochondrial cardiomyopathy,
Fig. 1 and Additional file 2 Table S1). HCM genes con-
sisted of 8 validated sarcomere genes and 25 putative
HCM genes [8].
DNA preparation
The details are described at Additional file 1 Method S1.
Library construction and sequencing of the HCM gene panel
and mtDNA
The details are described at Additional file 1 Method S2.
Identification of potential pathogenic mtDNA variants
Non-haplogroup-associated novel and rare variants were
evaluated for their potential pathogenicity based on vari-
ant location, amino acid change, and evolutionary con-
servation [9].
Data analysis of the HCM gene panel
The Burrows-Wheeler aligner algorithm with default pa-
rameters was used to align reads to the human reference
genome sequence GRCh37 [10]. SAMTools was used to
convert the sequence alignment map file to the BAM
format [11]. Sorting and removal of duplications were
performed using the Picard tool (http://broadinstitute.
github.io/picard/). GATK was used to perform indel rea-
ligning and base-quality score re-calibration [12]. Vari-
ants were annotated with ANNOVAR [13] and Variant
Effect Predictor (http://asia.ensembl.org/info/docs/tools/
vep/index.html). Only bases meeting the minimum base
quality (≥ 20) from reads are considered. Variants were
further filtered with altered allele frequency > 30%, 50×
coverage, and population frequency < 0.01 in the 1000
Genome Project, ESP6500, ExAC databases, and the Ko-
rean Reference Genome Database (http://152.99.75.168/
KRGDB), which was constructed with whole-genome se-
quencing data from 1100 Korean individuals. Prediction
of the potential pathogenicity was performed using
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Alamut® Visual software (Interactive Biosoftware, Rouen,
France), Human Gene Mutation Database professional
version, release 2016.1 (http://www.hgmd.org/), ClinVar,
and the Atlas of Cardiac Genetic Variation. The impact
of missense change was predicted with Align GVGD,
SIFT, PolyPhen and MutationTaster. Visual inspection
of candidate variants were performed using the Integra-
tive Genomics Viewer (IGV) [14] and we performed
Sanger confirmation of pathogenic variants which
showed unacceptable quality metrics. Variants were clas-
sified based on the American College of Medical Genet-
ics and Genomics standards and guidelines [15, 16].
Data analysis of the mitochondrial genome
The details are described in Additional file 1 Method S3.
Echocardiographic analysis
Comprehensive echo-Doppler evaluation was performed
according to current American Society of Echocardiog-
raphy guidelines [17]. A routine standard echocardiography
study was performed to measure systolic and diastolic
parameters as follows: LV end-diastolic volume and LV
end-systolic volume (LVESV) were measured with the
biplane Simpson’s method, and LV ejection fraction was
calculated. Left atrial (LA) volume was measured at the
end-systole by the ellipsoidal method, and LA volume index
was calculated as LA volume/body surface area (BSA). Peak
early (E) and late (A) diastolic mitral inflow velocities were
measured in apical four-chamber view. Tissue Doppler
interrogation was performed in the septal mitral annulus in
apical four-chamber view, followed by measurement of the
peak systolic mitral annulus velocity (s′) and early diastolic
mitral annulus peak velocity (e′). The ratio of E/e′ was
calculated. LV wall thickness was measured in all cross-
sectional planes. Continuous wave Doppler was used to
measure peak velocity across the LV outflow tract (LVOT),
and the pressure gradient was calculated using the
Bernoulli equation as follows: 4 × (peak velocity across the
LVOT) [18]. It was measured at resting and during Valsalva
maneuver. LVOT obstruction was defined as a systolic
pressure gradient ≥30mmHg. Contrast echocardiography
was performed in patients with a poorly defined LV border.
Mitral regurgitation (MR) degree was defined as trivial, I, II,
III, or IV according to regurgitation area.
Cardiac magnetic resonance imaging (CMR)
CMR was performed using a 1.5-T scanner (Magnetom
Avanto®; Siemens Medical Solutions, Erlangen,
Germany) with a phased array body coil. The LV 2-, 3-,
4-chamber, and short axis views were obtained using
cine images with steady-state free precession sequence.
The endocardial and epicardial borders were contoured
using a semi-automated method (Argus®; Siemens,
Germany or Qmass® MR 8.1; Medis, Leiden, the
Netherlands); subsequently, the LVEDV and LVESV
were measured. To determine the end-diastolic LV mass,
the difference between the epicardial and endocardial
areas for all slices was multiplied by the slice thickness
and section gap, and then multiplied by the specific
gravity of the myocardium (1.05 g/mL). Papillary muscle
mass was included in the LV cavity and excluded from
the LV mass measurements.
Fig. 1 The comprehensive hypertrophic cardiomyopathy (HCM)-specific panel consisted of 82 nuclear genes including (a) 33 sarcomere-
associated genes, (b) 5 phenocopy genes, and (c) 44 mitochondria-related nuclear DNA (nDNA) genes
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Mitral leaflet length measurement
AML lengths were measured in the parasternal long axis
(PLX) and apical three-chamber (3CH) views, the same
measurements from age- and sex-matched controls were
taken for comparison. In both views, AML lengths were
measured in diastole, with the leaflets maximally ex-
tended and parallel to the anterior septum, and defined
as the distance from the most distal extent of the anter-
ior leaflet to its insertion into the posterior aortic wall
(Fig. 2). The measurements were repeated in 10 ran-
domly selected patients to assess reproducibility.
LV geometry and mitral valve wall stress assessment
For end-systolic mitral valve wall stress assessment, the
index from LV side was roughly calculated as (LV end-
systolic pressure) × LVESV, where LV end-systolic pres-
sure was calculated as aorta end-systolic pressure (2 ×
systolic blood pressure + diastolic blood pressure/3) +
peak systolic LVOT pressure gradient. E/e′ × LA volume
was used for measurement of diastolic mitral valve wall
stress index from the LA side (LAWS).
Statistical analysis
Continuous variables with normal distributions are re-
ported as the mean ± standard deviation or 95% confi-
dence interval. Student’s t-tests were used to compare
the means of continuous variables that were approxi-
mately normally distributed between the two groups.
Normality was determined using the Shapiro-Wilk test.
Categorical variables are reported as counts (or percent-
ages) and were compared using chi-square tests. For
comparison of more than two groups, analysis of vari-
ance was performed with post-hoc analysis (LSD) for
subgroup comparison. For the reproducibility test,
paired sample t-tests and Pearson’s correlation coeffi-
cients were determined. All clinical statistical analyses
were performed using SPSS version 23.0 statistical
package (IBM Corp., Armonk, NY, USA). A two-sided
p-value < 0.05 was considered statistically significant.
Results
Baseline characteristics
The mean age of patients was 59 ± 14 years, and 63
(30%) were female. Of them, 49 (23%) had obstructive
HCM; 100 patients (47%) had ApHCM, and 64 (64%,
64/100) of these patients had pure-type ApHCM. The
AML lengths of patients with HCM, measured in both
PLX and 3CH, were significantly longer than those of
controls (32.1 ± 4.5 vs. 26.4 ± 2.9 mm in PLX; 28.3 ± 3.6
vs. 23.6 ± 3.1 mm in 3CH; both P < 0.001). Even after be-
ing indexed by BSA, patients with HCM had longer
AMLs than control (18.3 ± 2.8 vs. 14.0 ± 2.0 mm/m2 in
PLX; 16.1 ± 2.4 vs. 12.5 ± 1.8 mm/m2 in 3CH, P < 0.001)
(Fig. 3).
Genetic characteristics
Based on the American College of Medical Genetics and
Genomics guideline, [16] 67 of 211 (31.8%) cases had 71
pathogenic or likely pathogenic variants in 33
sarcomere-associated genes (33 MYBPC3, 19 MYH7, 14
TNNI3, 2 MYH6, 1 JPH2, 1 TNNC1, and 1 MYL3). Four
patients harbored more than one variant in HCM genes.
We identified homozygous or compound heterozygous
variants in MYBPC3 in one patient and co-variants in
three patients (two had MYBPC3 and MYH7, and one
had MYBPC3 and JPH2). Twenty-seven (13%) patients
had probably damaging mtDNA variants, 15 (7%) had
mitochondria-related nDNA variants, and 1 had a patho-
genic variant in GAA (Additional file 2 Table S2 and
Table S3). Patients with ApHCM had a lower prevalence
of sarcomere protein gene variants (41.4% vs. 20.8%, P =
0.001) than patients with non-ApHCM.
Fig. 2 Schematic illustration of anterior mitral leaflet distance measurement in the parasternal long axis view (a) and apical 3-chamber view (b)
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Correlation with mitral leaflet size
We observed significant correlations between average
AML length and BSA (r = 0.329, P < 0.001), LV end-
diastolic volume, LVESV (r = 0.341, P < 0.001), LV mass
by CMR (r = 0.338, P < 0.001), LV end-systolic wall stress
index, LA volume, and maximal thickness. Of these pa-
rameters, BSA showed significant and independent cor-
relation with average AML length (β = 0.292, P < 0.001);
hence, AML lengths indexed by BSA (iAML) were used
for further analyses. The average iAML of pure ApHCM
(n = 64) was significantly shorter than that of mixed or
non-ApHCM (n = 147; 16.6 ± 2.0 vs. 17.4 ± 2.4 mm/m2,
P = 0.025) along with a lower prevalence of sarcomere
protein gene mutation (19% vs. 36%, P = 0.006) (Table 1
and Fig. 3). Although the iAML of obstructive HCM was
not significantly higher than non-obstructive HCM
(17.8 ± 2.9 vs. 17.0 ± 2.1 mm/m2, P = 0.103), iAML was
significantly correlated with the LVOT peak pressure
gradient (resting and during Valsalva maneuver, r =
0.254, P = 0.001). Average iAML was significantly corre-
lated with age, LA volume, LAWS (r = 0.275, P < 0.001),
MR grade (r = 0.373, P < 0.001), and E/e′. In
multivariable analysis, LAWS was independently associ-
ated with the average iAML (β = 0.212, P = 0.012) (Table
1). The relationships between AML size and echocardio-
graphic parameters remained significant even after ex-
clusion of pure-type ApHCM.
Genetic relevance to mitral leaflet length
No significant difference was observed in iAML lengths
between the patients with and without pathogenic sarco-
mere protein gene variants. This non-significance
remained after exclusion of patients with pure-type
ApHCM. Among patients with sarcomere protein gene
variants, there was no significant difference between the
MYBPC3 (n = 32) and MYH7 (n = 17) groups (average
iAML, 16.8 ± 2.6 vs. 17.8 ± 2.2 mm/m2, P = 0.184). The
MYBPC3 mutation group has shorter AML-PLX values
(32.4 ± 4.4 vs. 30.6 ± 5.0 mm, P = 0.042), but iAML was
not significantly different. The sarcomere protein gene
variant group was further divided into thick filament
gene variant (n = 52) and thin filament or regulatory
gene variant (n = 15) groups. The thin filament group
showed larger AML size (31.9 ± 3.8 vs. 29.6 ± 3.8 mm/
Fig. 3 Comparison of indexed AML between sarcomere gene mutation positive and mutation negative patients along with comparison to
control (a). Comparison of AML-average between thick sarcomere gene variants and thin or regulatory sarcomere gene variants (b). Comparison
of indexed AML (c) and prevalence of sarcomere gene variants (d) between pure apical HCM and mixed or non-apical HCM. AML, anterior mitral
leaflet length; iAML, indexed AML, HCM, hypertrophic cardiomyopathy; bar represents mean ± standard error
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Table 1 Comparison between sarcomere protein gene variant group and non-variant group
Total (n = 211) Sarcomere protein gene variant group (n = 67)
Presence of sarcomere
protein gene variant group
(n = 67)
Absence of sarcomere
protein gene variant group
(n = 144)
P Thick filament gene
variant group (n =
52)
Thin filament or regulatory
gene variant group (n = 15)
P
Age, years 54.8 ± 14.3 61.3 ± 12.8 0.001 55.3 ± 13.0** 52.9 ± 18.5* 0.557
Women, n (%) 25 (37) 38 (26) 0.106 23 (44)* 2 (13)†† 0.029
Hypertension, n (%) 28 (42) 91 (63) 0.004 22 (42)** 6 (40)** 0.873
Diabetes, n (%) 12 (18) 27 (19) 0.884 9 (17) 3 (20) 0.811
Body surface area,
m2
1.76 ± 0.18 1.78 ± 0.21 0.596 1.74 ± 0.19 1.82 ± 0.13 0.135
FHx of SCD-1st, n
(%)
6 (9) 8 (6) 0.356 4 (8) 2 (13) 0.500
Syncope, n (%) 6 (9) 4 (3) 0.049 6 (12)* 0 (0)† 0.168
5-year SCD risk, %
(n = 123)
2.64 ± 1.51 2.01 ± 1.66 0.040 2.56 ± 1.38 2.88 ± 1.92 0.538
Echocardiography and CMR
ApHCM, n (%) 21 (31) 79 (55) 0.001 13 (25)** 8 (53)†† 0.037
LVOT PPG (rest),
mmHg
9.9 ± 11.6 15.0 ± 23.3 0.041 10.1 ± 12.4 9.5 ± 8.7 0.874
LVOT PPG
(Valsalva), mmHg
15.9 ± 19.2 28.2 ± 37.5 0.005 16.7 ± 20.8 12.8 ± 11.0 0.556
Dynamic
obstruction, n(%)
13 (19) 36 (25) 0.370 12 (23) 1 (7) 0.157
LVEDV, mL 70.6 ± 28.1 66.5 ± 21.9 0.252 71.1 ± 28.7 68.7 ± 26.6 0.770
LVESV, mL 25.4 ± 12.0 23.1 ± 8.8 0.106 26.1 ± 12.9 23.0 ± 7.9 0.374
LA volume index,
mL/m2
41.0 ± 22.0 34.8 ± 15.0 0.042 39.5 ± 19.1 46.1 ± 30.4* 0.307
MR grade 0.52 ± 0.35 0.47 ± 0.26 0.216 0.51 ± 0.39 0.57 ± 0.18 0.585
LV ejection
fraction, %
63.8 ± 7.3 64.9 ± 5.8 0.239 63.0 ± 7.8 66.6 ± 4.5 0.096
s′, cm/s 6.6 ± 1.6 6.8 ± 1.8 0.408 6.6 ± 1.6 6.6 ± 1.9 0.905
E/e′ 15.4 ± 6.7 14.6 ± 5.5 0.371 15.2 ± 6.6 16.3 ± 7.2 0.571
Maximal
thickness, mm
19.7 ± 3.7 18.6 ± 3.4 0.035 20.1 ± 3.5** 18.1 ± 4.1†† 0.061
LV mass index by
CMR, g/m2 (n =
132)
88.0 ± 21.1 84.9 ± 23.9 0.458 83.8 ± 18.3 102.9 ± 24.3* 0.014
AML lengths
AML-PLX, mm 31.4 ± 4.6 32.5 ± 4.4 0.109 30.8 ± 4.5* 33.5 ± 4.6 0.046
AML-3CH, mm 28.7 ± 3.9 28.1 ± 3.4 0.230 28.4 ± 3.9 30.0 ± 3.9 0.187
AML-average,
mm
30.1 ± 3.9 30.2 ± 3.5 0.848 29.6 ± 3.8 31.9 ± 3.8 0.045
iAML-PLX, mm/
m2
18.0 ± 2.8 18.5 ± 2.8 0.222 17.8 ± 2.8 18.4 ± 2.6 0.453
iAML-3CH, mm/
m2
16.5 ± 2.4 16.0 ± 2.3 0.164 16.5 ± 2.6 16.5 ± 1.7 0.941
iAML-average,
mm/m2
17.2 ± 2.4 17.2 ± 2.3 0.907 17.1 ± 2.5 17.5 ± 1.9 0.599
Thick filament genes include MYH7, MYBPC3, MYH6, and MYL3. *p < 0.05, **p < 0.01 versus absence of sarcomere gene variant group. AML anterior mitral leaflet,
PLX parasternal long axis view, 3CH three chamber view, iAML indexed AML, FHx family history, SCD-1st sudden cardiac death of 1st degree relatives, LV left
ventricular, LVEDV LV end-diastolic volume, LVESV LV end-systolic volume, LVESWS LV end-systolic wall stress, LA left atrial, LVOT LV outflow tract, PPG peak
pressure gradient, MR mitral regurgitation, s’ peak systolic septal mitral annular velocity, E/e’ ratio of early mitral inflow and annular velocity, CMR cardiac magnetic
resonance imaging †p < 0.05, ††p < 0.01 versus thick sarcomere gene mutation group
Chung et al. Cardiovascular Ultrasound           (2019) 17:21 Page 6 of 10
m2, P = 0.045 with average AML), but this was not sig-
nificant with the indexed value (P > 0.05) (Table 2). No
significant difference in mitral leaflet size was observed
upon classification of patients into non-variant, only
mitochondrial-related variant, only sarcomere protein
gene variant, and both sarcomere and non-sarcomere
gene variant groups (P > 0.05) (Table 3).
Measurement reproducibility of mitral leaflet length
With regard to intraobserver measurement variability,
there was no difference between the first and second
AML length measurements in PLX (29.8 ± 1.8 vs. 30.4 ±
2.1 mm, P = 0.161) or 3CH (27.8 ± 2.5 vs. 27.0 ± 2.6 mm,
P = 0.138). Correlation between measurements was good
for AML length in PLX (r = 0.835, P = 0.003) and 3CH
(r = 0.827, P = 0.003).
Discussion
In this study, we confirmed that mitral leaflet size was
significantly larger in patients with HCM than in con-
trols. Among these patients, significant and independent
correlations were observed between mitral leaflet size
and BSA, LV volume, LV mass by CMR, degree of MR
and LAWS. An extensive HCM panel showed no
independent relationships of genetic factors with mitral
leaflet size.
Chamber remodeling and hemodynamic load to mitral
leaflet length
Previous studies have shown that hemodynamic load in-
duces mitral leaflet development. In addition, adaptive
mitral leaflet growth may be observed in adults [19].
Our results also support the hypothesis that LV end-
systolic valve stress from the LV side and LA end-
diastolic valve wall stress from the LA side correlate with
AML size. We confirmed that leaflet lengths contribute
to the development of a trans-LVOT pressure gradient.
Our data showing a significant correlation between MR
grade and mitral leaflet length suggest that
hemodynamic load contributes to leaflet elongation.
However, whether increase in the trans-LVOT pressure
gradient and MR is a cause or result of AML elongation
is unclear. There are principally two types of cells found
in mitral leaflet tissue, namely, endothelial cells that
cover the surface of the cusps and interstitial cells (ICs)
that form a network within the extracellular matrix
(ECM) in the body of the cusp [6]. Both cell types ex-
hibit unique functions that are different from those of
Table 2 Univariate and multivariable analysis of correlation for anterior mitral leaflet lengths
Univariate analysis Multivariable Univariate analysis Multivariable
AML-PLX
(r)
AML-3CH
(r)
AML-average
(r)
AML-average (β, p
value)
iAML-PLX
(r)
iAML-3CH
(r)
iAML-average
(r)
iAML-average (β, p
value)
Age −0.123 − 0.221** − 0.198** 0.145* 0.081 0.117
BSA 0.299** 0.281** 0.329** 0.292 (< 0.001)
LVEDV 0.246** 0.297** 0.315**
LVESV 0.257** 0.340** 0.341** 0.207 (0.002)
LVESWS 0.239** 0.323** 0.317**
LV ejection
fraction
−0.118 −0.190** −0.164*
LA volume 0.132 0.197** 0.174* 0.124 0.189** 0.180**
Maximal
thickness
0.146* 0.225** 0.189**
LVOT-PPG
(Resting)
0.039 0.044 0.033 0.244** 0.225** 0.230**
LVOT-PPG
(Valsalva)
0.050 0.044 0.047 0.248** 0.240** 0.254** 0.110 (0.203)
MR grade 0.072 0.181** 0.147* 0.201 (0.004) 0.280** 0.390** 0.373** 0.146 (0.069)
E/e’ 0.023 −0.049 −0.007 0.238** 0.188** 0.239**
LA wall stress 0.079 0.071 0.096 0.242** 0.243** 0.275** 0.212 (0.012)
CMR findings (n = 132)
LV mass 0.301** 0.289** 0.338** 0.227 (0.013)†
LVEDV 0.156 0.365** 0.291**
LVESV 0,104 0.309** 0.228**
*p < 0.05, **p < 0.01, †adjustment for BSA, MR grade, LVEDV and LVESV by CMR; BSA body surface area, LVESWS LV end-systolic wall stress. See abbreviations in
Table 1
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Table 3 Clinical, anatomic, and hemodynamic characteristics according to the presence of genetic variant
No pathogenic or likely
pathogenic variant group
(n = 110)
1Only mitochondria related
nDNA or mtDNA variant group
(n = 33)
1Only sarcomere
gene variant group
(n = 58)
1Both sarcomere and
mitochondria-related gene vari-
ant group (n = 9)
§P
Age, years 61.1 ± 12.9 61.5 ± 12.3 54.4 ± 14.7**, † 57.0 ± 11.8 0.014
Women, n (%) 31 (28) 6 (18) 21 (36) 4 (44) 0.227
Hypertension, n (%) 69 (63) 21 (64) 26 (45) 2 (22) 0.019
Diabetes, n (%) 21 (19) 6 (18) 10 (17) 2 (22) 0.982
Body surface area,
m2
1.78 ± 0.21 1.79 ± 0.20 1.77 ± 0.19 1.70 ± 0.11 0.679
FHx of SCD-1st, n
(%)
6 (6) 2 (6) 5 (9) 1 (11) 0.820
Syncope, n (%) 3 (3) 1 (3) 5 (9) 1 (11) 0.270
5-year SCD risk, %
(n = 123)
2.01 ± 1.72 2.02 ± 1.45 2.73 ± 1.58* 2.10 ± 0.97 0.163
Echocardiography and CMR
ApHCM, n (%) 57 (52) 22 (67) 19 (33) 2 (22) 0.004
LVOT PPG (rest),
mmHg
17.4 ± 26.5 8.0 ± 7.4* 10.5 ± 11.9 5.2 ± 2.1 0.005
LVOT PPG
(Valsalva), mmHg
31.2 ± 40.7 17.4 ± 23.4 18.5 ± 21.1* 6.2 ± 2.9 0.025
Dynamic
obstruction, n
(%)
31 (28) 5 (15) 13 (22) 0 (0) 0.142
LVEDV, mL 66.8 ± 22.5 66.2 ± 20.6 69.9 ± 27.1 71.3 ± 34.1 0.730
LVESV, mL 22.5 ± 8.4 24.8 ± 9.9 24.6 ± 10.2 29.2 ± 20.3 0.145
LA volume
index, mL/m2
35.2 ± 14.9 31.8 ± 11.1 40.6 ± 22.9† 43.6 ± 15.7 0.051
MR grade 0.49 ± 0.28 0.40 ± 0.21 0.52 ± 0.36 0.56 ± 0.17 0.217
LV ejection
fraction, %
65.7 ± 5.0 62.5 ± 7.6* 64.3 ± 6.9 61.2 ± 8.7* 0.021
s′, cm/s 6.8 ± 1.7 6.9 ± 2.1 6.6 ± 1.7 7.0 ± 1.4 0.748
E/e′ 14.8 ± 5.5 13.9 ± 5.3 15.6 ± 6.9 13.5 ± 4.6 0.462
Maximal
thickness, mm
18.7 ± 3.6 18.1 ± 2.6 19.6 ± 3.8† 19.8 ± 3.5 0.164
LV mass index
by CMR, g/m2
(n = 132)
85.1 ± 23.9 84.3 ± 24.3 88.5 ± 22.0 84.7 ± 15.9 0.885
AML lengths
AML-PLX, mm 32.4 ± 4.5 32.5 ± 4.3 31.7 ± 4.7 29.7 ± 3.7 0.260
AML-3CH, mm 28.2 ± 3.5 27.7 ± 3.0 28.8 ± 3.9 28.4 ± 4.3 0.633
AML-average,
mm
30.2 ± 3.6 30.2 ± 3.2 30.3 ± 3.9 29.1 ± 3.6 0.834
iAML-PLX, mm/
m2
18.4 ± 2.7 18.4 ± 2.9 18.0 ± 2.9 17.5 ± 2.1 0.671
iAML-3CH, mm/
m2
16.1 ± 2.4 15.7 ± 1.9 16.4 ± 2.4 16.8 ± 2.5 0.408
iAML-average,
mm/m2
17.2 ± 2.3 17.0 ± 2.2 17.2 ± 2.4 17.1 ± 2.1 0.981
One patient with pathogenic variants in GAA was excluded. 1Pathogenic or likely pathogenic mutation or damaging mtDNA variant; §p, p-value for ANOVA. *p <
0.05, **p < 0.01 versus no pathogenic or likely pathogenic variant group; †p < 0.05 versus mitochondrial related variant group; See abbreviations in Table 1
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other endothelial cells and ICs found throughout the
body. Valve ICs express a complex pattern of cell sur-
face, cytoskeletal, and muscle proteins. These are able to
bind to- and communicate with each other and the
ECM. Although, endothelial cells on the outflow and in-
flow surfaces of the valve differ from one another, [6, 20]
valve stresses on both sides would promote leaflet elong-
ation even in overt HCM status as supported by our
study results.
Genetic contribution to mitral leaflet length
In our results, patients with HCM had larger iAMLs
than age- and sex-matched controls, indicating that gen-
etic factors contribute to mitral leaflet elongation. How-
ever, we could not find a direct relationship between
leaflet size and sarcomere genes, phenocopy genes,
mitochondria-related nDNA or mtDNA in the stage of
overt HCM. Previous some studies showed that sarco-
mere gene mutations promote mitral leaflet elongation
in subclinical HCM [2, 7], however after development of
myocardial hypertrophy and LV remodeling,
hemodynamic and geometrical factors predominantly
affect mitral leaflet elongation. Therefore, mitral leaflet
elongation could be a secondary phenotype following
myocardial hypertrophy. These findings are supported
by the previous study results of larger leaflets size in
overt HCM patients than in subclinical HCM, in spite of
same sarcomere gene mutations [2, 7].
Embryologically, the mitral leaflet originates from the
atrio-ventricular annulus, which is adjacent to the basal
portion of the left ventricle [20]. According to our study,
leaflet size was smaller for pure ApHCM than for others,
including asymmetrical basal septal hypertrophy, sug-
gesting that hypertrophy signals affect adjacent AML
growth through hemodynamic load or genetic predispos-
ition to basal myocardial hypertrophy. Why the AML is
larger in classical HCM than in ApHCM might be ex-
plained by genetic contribution, because of more preva-
lent in mitochondria-related gene or mtDNA mutations
and less prevalent in sarcomere gene mutations in
ApHCM. Troponin I and T genes, included in thin
sarcomere protein gene, were shown to be related to
valve IC activation [5]. Thin filament or regulatory genes
were more related to mitral leaflet elongation in the
present and a previous study [4], which suggests that mi-
tral leaflet size is determined by multiple genes and
modified by chronic hemodynamic load and chamber re-
modeling. However, this relationship was significantly
attenuated after controlling for body size or LV size.
A recent study revealed that mutations in DCHS1
gene cause mitral valve prolapse with elongation [21],
which suggests that MV specific gene might directly
affect mitral leaflet enlargement even in HCM. There-
fore, studies for revealing genetic factors not only
sarcomere genes but also genes coding MV ICs need to
be performed in HCM. This effort would open new
therapeutic option for preventing obstructive HCM by
genetic manipulation.
Limitations
This study has several limitations. First, only AML size
was measured with echocardiography. Although cardio-
vascular magnetic resonance (CMR) has been used good
imaging modality for both AML and posterior mitral
leaflet, a review of MV leaflet size showed that CMR
cannot perfectly measure the distance. AML usually rep-
resents the main pathology in HCM, and leaflet length
measurements were performed in two different views,
with the average value used to reduce measurement er-
rors. Second, our extensive HCM gene panel and
mtDNA analysis did not assess rare variant contribution
to mitral leaflet size. Third, the enrolled study popula-
tion number was not large enough to reach statistical
power. The cost of next-generation sequencing is con-
tinuously decreasing; hence, extensive gene panel ana-
lyses to evaluate multigenic contributions to leaflet size
in a large HCM registry is warranted.
Conclusion
Mitral leaflet elongation was a unique finding of HCM.
However, the leaflet size was more related to LV geom-
etry and hypertrophy pattern rather than genetic factors
within overt HCM, suggesting that mitral leaflet elong-
ation is due to gene–hemodynamic interaction and
chamber remodeling.
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